chloroquine has been researched along with Porphyria Cutanea Tarda in 29 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Porphyria Cutanea Tarda: An autosomal dominant or acquired porphyria due to a deficiency of UROPORPHYRINOGEN DECARBOXYLASE in the LIVER. It is characterized by photosensitivity and cutaneous lesions with little or no neurologic symptoms. Type I is the acquired form and is strongly associated with liver diseases and hepatic toxicities caused by alcohol or estrogenic steroids. Type II is the familial form.
| Excerpt | Relevance | Reference |
|---|---|---|
| "to assess the efficacy, tolerance and determinants for relapse in patients with porphyria cutanea tarda treated with low-dose oral chloroquine." | 9.07 | Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload. ( Ena, J; Enríquez-De-Salamanca, R; Valls, V, 1994) |
| "Chloroquine is a drug with over 60 years of safe clinical use in the treatment of malaria." | 8.81 | [Chloroquine--miscellaneous properties of the antimalarial drug]. ( Jarzyna, R, 2002) |
| "High-dose chloroquine therapy for porphyria cutanea tarda is rarely used now because of its hepatic side-effects." | 7.74 | Porphyria cutanea tarda: effects and risk factors for hepatotoxicity from high-dose chloroquine treatment. ( Olsson, R; Rossmann-Ringdahl, I, 2007) |
| "To examine the role of hemochromatosis (HFE) gene mutations, which are associated with porphyria cutanea tarda (PCT), in the therapeutic response to chloroquine." | 7.72 | Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. ( Doss, MO; Köstler, E; Richter, M; Schuppan, D; Stölzel, U; Tannapfel, A; Wittekind, C; Wollina, U, 2003) |
| "Chloroquine may improve cutaneous symptoms and liver disease manifestations in patients with porphyria cutanea tarda." | 7.69 | [Treatment of porphyria cutanea tarda with chloroquine and its effect on associated liver disease: retrospective analysis]. ( Armas, R; Krause, P; Parraguez, A; Ramón Soto, J; Wolff, C, 1996) |
| "Chloroquine treatment resulted in PCT remission (clinical and biochemical) and in 81% to an improvement of liver morphology." | 5.35 | Does chloroquine therapy of porphyria cutanea tarda influence liver pathology? ( Koch, A; Köstler, E; Riedel, H; Stölzel, U; Wollina, U, 2009) |
| "to assess the efficacy, tolerance and determinants for relapse in patients with porphyria cutanea tarda treated with low-dose oral chloroquine." | 5.07 | Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload. ( Ena, J; Enríquez-De-Salamanca, R; Valls, V, 1994) |
| " Porphyria cutanea tarda can be effectively treated by phlebotomy or low dose chloroquine." | 4.81 | Management of acute and cutaneous porphyrias. ( Badminton, MN; Elder, GH, 2002) |
| "Chloroquine is a drug with over 60 years of safe clinical use in the treatment of malaria." | 4.81 | [Chloroquine--miscellaneous properties of the antimalarial drug]. ( Jarzyna, R, 2002) |
| "High-dose chloroquine therapy for porphyria cutanea tarda is rarely used now because of its hepatic side-effects." | 3.74 | Porphyria cutanea tarda: effects and risk factors for hepatotoxicity from high-dose chloroquine treatment. ( Olsson, R; Rossmann-Ringdahl, I, 2007) |
| "To examine the role of hemochromatosis (HFE) gene mutations, which are associated with porphyria cutanea tarda (PCT), in the therapeutic response to chloroquine." | 3.72 | Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. ( Doss, MO; Köstler, E; Richter, M; Schuppan, D; Stölzel, U; Tannapfel, A; Wittekind, C; Wollina, U, 2003) |
| "Chloroquine treatment resulted in PCT remission (clinical and biochemical) and in 81% to an improvement of liver morphology." | 1.35 | Does chloroquine therapy of porphyria cutanea tarda influence liver pathology? ( Koch, A; Köstler, E; Riedel, H; Stölzel, U; Wollina, U, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.45) | 18.7374 |
| 1990's | 13 (44.83) | 18.2507 |
| 2000's | 11 (37.93) | 29.6817 |
| 2010's | 4 (13.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Estrada, A | 2 |
| Gomez-Morales, LB | 1 |
| García-Morillo, JS | 1 |
| Wallaeys, E | 1 |
| Thierling, U | 1 |
| Lang, E | 1 |
| Neumann, NJ | 1 |
| Frank, J | 1 |
| Merk, HF | 1 |
| Ghosh, SK | 1 |
| Bandyopadhyay, D | 1 |
| Chatterjee, G | 1 |
| Ghosh, AP | 1 |
| Barbieri, L | 1 |
| Macrì, A | 1 |
| Lupia Palmieri, G | 1 |
| Aurizi, C | 1 |
| Biolcati, G | 1 |
| Wollina, U | 3 |
| Köstler, E | 4 |
| Koch, A | 1 |
| Riedel, H | 2 |
| Stölzel, U | 2 |
| Lee, CH | 1 |
| Yuen, MM | 1 |
| Chow, WS | 1 |
| Tso, AW | 1 |
| Yeung, CK | 1 |
| Chan, JC | 1 |
| Chau, CH | 1 |
| Lam, KS | 1 |
| Schuppan, D | 1 |
| Richter, M | 1 |
| Doss, MO | 2 |
| Wittekind, C | 1 |
| Tannapfel, A | 1 |
| LONDON, ID | 1 |
| Toll, A | 1 |
| Celis, R | 1 |
| Ozalla, MD | 1 |
| Ercilla, MG | 1 |
| Herrero, C | 1 |
| Rossmann-Ringdahl, I | 1 |
| Olsson, R | 1 |
| Liu, AC | 1 |
| Freesemann, A | 1 |
| Frank, M | 1 |
| Sieg, I | 1 |
| Valls, V | 1 |
| Ena, J | 1 |
| Enríquez-De-Salamanca, R | 1 |
| Belda Mira, A | 1 |
| Rovira Daudí, E | 1 |
| Díaz Sánchez, F | 1 |
| Michavila Gómez, J | 1 |
| Bunk, A | 1 |
| Drago, F | 1 |
| Battifoglio, ML | 1 |
| Gelati, G | 1 |
| Rebora, A | 1 |
| Lacour, JP | 1 |
| Wallace, DJ | 1 |
| Hoegl, L | 1 |
| Thoma-Greber, E | 1 |
| Röcken, M | 1 |
| Wolff, C | 1 |
| Armas, R | 1 |
| Krause, P | 1 |
| Parraguez, A | 1 |
| Ramón Soto, J | 1 |
| Adjarov, D | 1 |
| Naydenova, E | 1 |
| Ivanov, E | 1 |
| Ivanova, A | 1 |
| Kondo, M | 1 |
| Yano, Y | 1 |
| Nordmann, Y | 1 |
| Puy, H | 1 |
| Deybach, JC | 1 |
| Khoo, BP | 1 |
| Tay, YK | 1 |
| Martínez, A | 1 |
| Morales, R | 1 |
| Brethauer, U | 1 |
| Jiménez, M | 1 |
| Alarcón, R | 1 |
| Badminton, MN | 1 |
| Elder, GH | 1 |
| Jarzyna, R | 1 |
7 reviews available for chloroquine and Porphyria Cutanea Tarda
| Article | Year |
|---|---|
[Porphyria cutanea tara].
Topics: Alcoholism; Causality; Chloroquine; Comorbidity; Germany; Hemochromatosis; Hepatitis C; Humans; Iron | 2016 |
Therapy of porphyria cutanea tarda.
Topics: Chloroquine; Deferoxamine; Erythropoietin; Humans; Iron; Phlebotomy; Porphyria Cutanea Tarda; Renal | 2005 |
The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review.
Topics: Antimalarials; Antiphospholipid Syndrome; Autoimmune Diseases; Chloroquine; Controlled Clinical Tria | 1996 |
[Porphyria cutanea tarda].
Topics: Biomarkers; Bloodletting; Chloroquine; Diagnosis, Differential; Hemin; Humans; Mutation; Porphyria C | 1998 |
[Hepatic porphyria].
Topics: Adult; Analgesics, Opioid; Antipsychotic Agents; Charcoal; Child; Child, Preschool; Chloroquine; Chl | 1999 |
Management of acute and cutaneous porphyrias.
Topics: Arginine; beta Carotene; Chloroquine; Estrogens; Ethanol; Heme; Humans; Phlebotomy; Porphyria Cutane | 2002 |
[Chloroquine--miscellaneous properties of the antimalarial drug].
Topics: Animals; Antimalarials; Arthritis, Rheumatoid; Chloroquine; Humans; Lupus Vulgaris; Malaria; Porphyr | 2002 |
2 trials available for chloroquine and Porphyria Cutanea Tarda
| Article | Year |
|---|---|
Treatment of porphyria cutanea tarda by the effect of chloroquine on the liver.
Topics: Adult; Chloroquine; Chromatography, High Pressure Liquid; Chronic Disease; Female; Humans; Liver; Li | 1995 |
Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload.
Topics: Administration, Oral; Adult; Aged; Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Ir | 1994 |
20 other studies available for chloroquine and Porphyria Cutanea Tarda
| Article | Year |
|---|---|
Sporadic porphyria cutanea tarda: treatment with chloroquine decreases hyperglycemia and reduces development of metabolic syndrome.
Topics: Adolescent; Adult; Chloroquine; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglob | 2014 |
[Porphyria cutanea tarda with sclerodermatous changes and hemochromatosis].
Topics: Chloroquine; Female; Hemochromatosis; Hemochromatosis Protein; Histocompatibility Antigens Class I; | 2014 |
Porphyria cutanea tarda.
Topics: Adult; Biomarkers; Chloroquine; Humans; Male; Porphyria Cutanea Tarda; Porphyrins; Skin | 2008 |
Association between porphyria cutanea tarda and beta-thalassemia major.
Topics: Adult; Anemia; beta-Thalassemia; Chloroquine; Deferoxamine; Female; Hepatitis C; Humans; Iron Overlo | 2009 |
Does chloroquine therapy of porphyria cutanea tarda influence liver pathology?
Topics: Antimalarials; Biopsy; Chloroquine; Dose-Response Relationship, Drug; Female; Hemochromatosis Protei | 2009 |
A man with a blistering eruption and tuberculosis.
Topics: Antimalarials; Antitubercular Agents; Chloroquine; Diagnosis, Differential; Drug Therapy, Combinatio | 2012 |
Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Chloroquine; Drug Administration Schedule; Fem | 2003 |
Porphyria cutanea tarda; report of case successfully treated with chloroquine.
Topics: Animals; Chloroquine; Humans; Porifera; Porphyria Cutanea Tarda; Porphyrias; Skin Diseases | 1957 |
Haemochromatosis gene mutations and response to chloroquine in sporadic porphyria cutanea tarda.
Topics: Chloroquine; Hemochromatosis; Humans; Medical Records; Mutation; Phlebotomy; Porphyria Cutanea Tarda | 2006 |
Porphyria cutanea tarda: effects and risk factors for hepatotoxicity from high-dose chloroquine treatment.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antimalarials; Chemical and Drug Induced Liver | 2007 |
Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda.
Topics: Antimalarials; Chloroquine; Coproporphyrins; Female; Humans; Liver; Malaria; Middle Aged; Porphyria | 1995 |
[Porphyria cutanea tarda and human immunodeficiency virus infection. Apropos of 2 further cases].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chloroquine; Drug Therapy, Combination; HIV Infectio | 1994 |
[Liver coin lesions in porphyria cutanea tarda].
Topics: Chloroquine; Diagnosis, Differential; Humans; Liver; Liver Function Tests; Male; Middle Aged; Porphy | 1993 |
Very low-dose chloroquine treatment for porphyria cutanea tarda.
Topics: Aged; Antimalarials; Chloroquine; Female; Humans; Porphyria Cutanea Tarda | 1995 |
[Monthly question: how should porphyria cutanea tarda be treated?].
Topics: Chloroquine; Female; Humans; Male; Phlebotomy; Porphyria Cutanea Tarda; Treatment Outcome | 1996 |
[Porphyria cutanea tarda (type 1) in HIV infection].
Topics: Antirheumatic Agents; Biopsy; Chloroquine; Diagnosis, Differential; HIV Infections; Humans; Male; Mi | 1996 |
[Treatment of porphyria cutanea tarda with chloroquine and its effect on associated liver disease: retrospective analysis].
Topics: Aged; Chloroquine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Porphyria Cutanea Tarda; Re | 1996 |
Choice of therapy in porphyria cutanea tarda.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chloroquine; Combined Modality Therapy; Female | 1996 |
Porphyria cutanea tarda.
Topics: Biopsy; Chloroquine; Combined Modality Therapy; Diagnosis, Differential; Humans; Male; Middle Aged; | 2000 |
Porphyria cutanea tarda affecting lower lip.
Topics: Administration, Topical; Anti-Inflammatory Agents; Cheilitis; Chloroquine; Dermatologic Agents; Diag | 2000 |